Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics says global consumer goods company is looking at its technology

The company has been speaking to a range of commercial partners interested in evaluating its SkinBiotix technology ahead of its human studies, which are scheduled to commence later this year
Fresh faced model
SkinBioTherapeutics will share a sample of its material against which the third party will conduct its own in-house assessment

Skin health specialist SkinBioTherapeutics PLC (LON:SBTX) has granted access to its proprietary SkinBiotix technology to a major, global consumer goods company.

Having shared the initial pre-clinical data with a number of interested parties, one potential partner to date has progressed to a material transfer agreement - a standard agreement governing the transfer of material between parties enabling the recipient to assess the technology.

Should the unnamed consumer goods company like what it sees, the arrangement could lead to a commercial arrangement between the two companies.

While at this stage there can be no certainty that discussions will progress further than the initial sharing of the technology, SkinBioTherapeutics is encouraged by the level of interest that has been shown in its pre-clinical data.

WATCH: Industry heavyweights 'sitting up and taking notice' of SkinBio's technology

The company is initially targeting cosmetic skin care and in this market, SkinBioTherapeutics' skin microbiome technology is unusual in that its properties are supported by scientific data, SkinBio said.

The demonstrated properties support potential opportunities for the company in cosmetics, anti-infectives and dermatological indications (e.g. eczema).

"Whilst these are early discussions, we are encouraged that a company of this calibre wants to look at our technology more closely through an MTA. Even at this early stage of its development, we are pleased to see that SkinBiotix is starting to generate a buzz in the skin care industry," said Dr Cath O’Neill, the chief executive officer of SkinBioTherapeutics. 

Motif’s joint broker, Northland Capital Partners, said: “It is encouraging that SkinBio Therapeutics is progressing to an MTA with a global consumer goods company. This demonstrates the potential commercial promise of the company’s technology.”

Shares in Motif were up 5.9% at 9p in lunchtime trading.

--- adds broker comment and share price reaction ---  

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
cannabis
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use